Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

Study identifier:D6402C00003

ClinicalTrials.gov identifier:NCT04798222

EudraCT identifier:2021-000483-30

CTIS identifier:N/A

Study Complete

Official Title

An Open-label, Randomized, Parallel Group, Four/Five Period, Eight Treatment Cross-over, Single Oral Dose Study to Assess the Relative Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

Medical condition

heart failure

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H

Sex

All

Actual Enrollment

20

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 29 Jun 2021
Primary Completion Date: 03 Sept 2021
Study Completion Date: 03 Sept 2021

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Basic Science

Verification:

Verified 01 Jun 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria